|Articles|August 12, 2019

Signant Health Launches Partner Program

Signant Health, a provider of technology for clinical research,has announced the launch of the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. 

 

Chris Crucitti, Chief Commercial Officer of Signant Health explains, “This programputs in place the infrastructure needed to ensure the success of our CRO partners across Signant’s solution portfolio. We will remain ever committed to the traditional support of our partners via protocol design and optimization, eCOA data collection, data quality oversight, patient engagement, eConsent and clinical supply management. However, the needs and challenges of CROs are more complex and expansive today than ever before, just as they are for the sponsors we jointly support. The time is right for us to make a landmark investment in our partners so that together we can more powerfully impact data quality and clinical trial execution. When our partners succeed, clinical research succeeds.”

 

With approximately 50 percent of clinical research activities being outsourced by pharmaceutical companies to CROs that offer full services across the entire drug development process, there is both a growing need for CROs to deliver technology in support of services and an increasing demand to leverage technology to differentiate those services. This Partner Program is designed to extend Signant’s 20 years of experience-in clinical and scientific practices, operations, and global requirements-to its partners.


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.